Is There Already a Need of Reckoning on Cancer Immunotherapy?
Κύριοι συγγραφείς: | Pierpaolo Correale, Francesca Pentimalli, Giovanni Baglio, Marjia Krstic-Demonacos, Rita Emilena Saladino, Antonio Giordano, Luciano Mutti |
---|---|
Μορφή: | Άρθρο |
Γλώσσα: | English |
Έκδοση: |
Frontiers Media S.A.
2021-03-01
|
Σειρά: | Frontiers in Pharmacology |
Θέματα: | |
Διαθέσιμο Online: | https://www.frontiersin.org/articles/10.3389/fphar.2021.638279/full |
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Coronavirus Disease (Covid-19): What Are We Learning in a Country With High Mortality Rate?
ανά: Luciano Mutti, κ.ά.
Έκδοση: (2020-05-01) -
Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
ανά: Roger Y. Kim, MD, κ.ά.
Έκδοση: (2021-06-01) -
Intratumor microbiota as a novel potential prognostic indicator in mesothelioma
ανά: Francesca Pentimalli, κ.ά.
Έκδοση: (2023-03-01) -
Current status and progress in immunotherapy for malignant pleural mesothelioma
ανά: Boyang Sun, κ.ά.
Έκδοση: (2022-06-01) -
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
ανά: Valerio Nardone, κ.ά.
Έκδοση: (2021-11-01)